Quantification of Circulating tumor DNA to assess treatment response in metastatic prostate cancer patients
Recruiting
- Conditions
- metastatic prostate cancer
- Registration Number
- NL-OMON24467
- Lead Sponsor
- Erasmus Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 95
Inclusion Criteria
Histologically or cytologically confirmed adenocarcinoma of the prostate.
- Measurable metastatic lesion(s) according to PCWG2 and/or RECIST 1.1 criteria
Exclusion Criteria
NA
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of mPC patients with quantifiable ctDNA taken pre-treatment.
- Secondary Outcome Measures
Name Time Method - The percentage of blood samples with sufficient ctDNA.<br /><br>- The interval between detected ctDNA and PSA response during treatment.<br /><br>- The correlation between ctDNA response and progression-free survival.<br>